Miners have helped the FTSE 100 end a choppy session on a high, buoyed by rising metal prices and offsetting falls for 'defensive' shares.
The UK blue-chip index closed 22 points, or 0.3%, higher at 7,709, with mining stocks leading the way.
Tobacco stocks were also under pressure, with Imperial Brands (IMB) down 1.9% at £26.32.
Insurers meanwhile dipped on a report in The Information claiming Amazon (AMZN.O) had considered offering home insurance.
On the FTSE 250, shares in RPC (RPC) tumbled 11.9% to 681.7p as investors baulked at the plastic packaging maker's scale of spending, which hit cash flow.
'RPC has reported numbers in line with expectations, posted healthy organic growth and increased the dividend for the 25th year in a row,' said Nicholas Hyett, equity analyst at Hargreaves Lansdown.
'So why are the shares down? Well cash flow is perhaps a little disappointing and the worries about increased scrutiny haven't been dispelled. But overall it feels like the company is being harshly treated.'
The slump in the shares will a blow to the stocks' high conviction fund manager backers. At the end of April, RPC represented 4% of Frederik Nassauer's £245 million Standard Life Investments UK Equity High Alpha fund and 4% of Jamie Seaton's £323 million GVQ UK Focus fund.
Scott McKenzie meanwhile held 4.8% of his £8 million Saracen UK Alpha fund in the stock at the end of May. But RPC's slide was offset by the 2.5% jump in the shares of his top holding, Alpha Financial Markets Consulting (AFM), which makes up 7% of the portfolio.
Shares in the group, also the top holding in McKenzie's £3 million Saracen UK Income fund, rallied on strong full-year results.
WH Smith (SMDS) meanwhile jumped to the top of the FTSE 250, up 6.2% at £20.98, on an improved high street performance alongside continued growth in the travel division.
Among 'small-cap' stocks, Oxford Biomedica (OXB) surged 18.9% to 861p after the gene and cell therapy company signed a licensing deal with Axovant Sciences (AXON.O) to develop a therapy for Parkinson's disease.